Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“RECAST, phase II
1L mCRC: FOLFIRI + RAM vs FOLFOXIRI + RAM
ORR 59.3% vs 60.3%
PFS 11.5 vs 10.5 mo
OS: 32.6 vs 28.2 mo, increased ETS
Increased toxicity with triplet.
Do we really need FOLFOXIRI + RAM in 1L?”
Article: Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
Authors: Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, Takeshi Yamada, Takahiro Tsushima, Seiichiro Mitani, Kazuhiro Shiraishi, Hisateru Yasui, Hiroki Hara, Kenro Hirata, Taito Esaki, Yudai Shinohara, Takao Tsuzuki, Shinya Kajiura, Toshiki Masuishi, Naoki Izawa, Eishi Baba, Kohei Murata, Naoya Akazawa, Yozo Suzuki, Hironaga Satake, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura, Hisato Kawakami, Shuichi Hironaka, Kei Muro
Other articles featuring Nieves Martinez Lago on OncoDaily.